Disease · MONDO_0005147
Comparisons in its trials260
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 260
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Type 1 Diabetes vs Type 2 Diabetes: serious adverse events | 130 of 13,529 | 80 of 37,641 | 51,170 | NCT00659295 | Trial comparisons |
| Sotagliflozin 400 mg vs Placebo: deaths from any cause | 1 of 699 | 0 of 703 | 1,402 | NCT02531035 | Trial comparisons |
| Sotagliflozin 400 mg vs Placebo: serious adverse events | 48 of 699 | 23 of 703 | 1,402 | NCT02531035 | Trial comparisons |
| LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: serious adverse events | 117 of 663 | 92 of 449 | 1,112 | NCT01454284 | Trial comparisons |
| Insulin Degludec (IDeg) vs Insulin Glargine (IGlar): serious adverse events | 58 of 454 | 70 of 460 | 914 | NCT02034513 | Trial comparisons |
| 500 U/mL Insulin Efsitora Alfa vs 100 U/mL Insulin Degludec: deaths from any cause | 0 of 343 | 1 of 349 | 692 | NCT05463744 | Trial comparisons |
| 500 U/mL Insulin Efsitora Alfa vs 100 U/mL Insulin Degludec: serious adverse events | 45 of 343 | 24 of 349 | 692 | NCT05463744 | Trial comparisons |
| HOE901-U300 vs Lantus: deaths from any cause | 0 of 320 | 0 of 318 | 638 | NCT02688933 | Trial comparisons |
| HOE901-U300 vs Lantus: serious adverse events | 17 of 320 | 14 of 318 | 638 | NCT02688933 | Trial comparisons |
| IDeg OD vs IGlar OD: serious adverse events | 71 of 472 | 29 of 154 | 626 | NCT00982228 | Trial comparisons |
| SAR341402 vs NovoLog/NovoRapid: deaths from any cause | 1 of 301 | 2 of 296 | 597 | NCT03211858 | Trial comparisons |
| SAR341402 vs NovoLog/NovoRapid: serious adverse events | 36 of 301 | 29 of 296 | 597 | NCT03211858 | Trial comparisons |
| Insulin Icodec + Insulin Aspart vs Insulin Degludec + Insulin Aspart: deaths from any cause | 1 of 290 | 0 of 292 | 582 | NCT04848480 | Trial comparisons |
| Insulin Icodec + Insulin Aspart vs Insulin Degludec + Insulin Aspart: serious adverse events | 24 of 290 | 20 of 292 | 582 | NCT04848480 | Trial comparisons |
| Inhaled Insulin vs Subcutaneous Insulin: serious adverse events | 50 of 290 | 65 of 290 | 580 | NCT00137046 | Trial comparisons |
| Gan & Lee Insulin Glargine Injection vs Lantus®: Number of Subjects With Confirmed Positive AIA After Baseline. | 102 of 287 | 103 of 289 | 576 | NCT03371082 | Trial comparisons |
| Gan & Lee Insulin Glargine Injection vs Lantus®: deaths from any cause | 0 of 287 | 1 of 289 | 576 | NCT03371082 | Trial comparisons |
| Gan & Lee Insulin Glargine Injection vs Lantus®: serious adverse events | 10 of 287 | 14 of 289 | 576 | NCT03371082 | Trial comparisons |
| TI + Insulin Glargine vs Insulin Aspart + Insulin Glargine: serious adverse events | 52 of 293 | 47 of 272 | 565 | NCT00308308 | Trial comparisons |
| Mylan's Insulin Glargine vs Lantus®: deaths from any cause | 2 of 280 | 1 of 278 | 558 | NCT02227862 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005147/comparisons